{"entity":{"type":"insider","cik":"0001507678","url":"/insider/0001507678","json_url":"/insider/0001507678.json","name":"Legorreta Pablo G.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":7,"first":"2020-06-22","last":"2024-06-14","span_basis":"filed_date"},"name_variants":[{"name":"Legorreta Pablo G.","source":"filing","n_filings":7,"first_seen":"2020-06-22","last_seen":"2024-06-14"}],"transactions":[{"id":2770884,"accession":"0000950170-24-073633","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-073633","line_url":"/filing/0000950170-24-073633#line-1","is_derivative":false,"issuer_cik":"0001507678","issuer_name":"PROKIDNEY CORP.","issuer_ticker":"PROK","issuer_name_source":null,"issuer_url":"/issuer/0001507678","owner_cik":null,"owner_name":"Legorreta Pablo G.; Tolerantia, LLC","owner_display_name":"Legorreta Pablo G.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Class A Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":22617909.0,"shares_display":"22,617,909","price_per_share":2.42,"price_display":"2.42","price_state":"stated","total_value":54735339.78,"total_display":"54,735,339.78","total_whole":"54,735,340","shares_owned_after":22617909.0,"shares_owned_after_display":"22,617,909","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-06-13","filed_date":"2024-06-14","scope":"insider"},{"id":8022869,"accession":"0001209191-23-040024","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-040024","line_url":"/filing/0001209191-23-040024#line-1","is_derivative":false,"issuer_cik":"0001507678","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001507678","owner_cik":"0001507678","owner_name":"Legorreta Pablo G.","owner_display_name":"Legorreta Pablo G.","owner_url":"/insider/0001507678","role":"Director, Officer (CEO, Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, Chairman of the Board","security_title":"Class A ordinary shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":130000.0,"shares_display":"130,000","price_per_share":29.5136,"price_display":"29.51","price_state":"stated","total_value":3836768.0,"total_display":"3,836,768.00","total_whole":"3,836,768","shares_owned_after":600000.0,"shares_owned_after_display":"600,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-28","filed_date":"2023-06-28","scope":"insider"},{"id":8154330,"accession":"0001209191-23-036624","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-036624","line_url":"/filing/0001209191-23-036624#line-2","is_derivative":false,"issuer_cik":"0001507678","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001507678","owner_cik":"0001507678","owner_name":"Legorreta Pablo G.","owner_display_name":"Legorreta Pablo G.","owner_url":"/insider/0001507678","role":"Director, Officer (CEO, Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, Chairman of the Board","security_title":"Class A ordinary shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":45000.0,"shares_display":"45,000","price_per_share":32.7756,"price_display":"32.78","price_state":"stated","total_value":1474902.0,"total_display":"1,474,902.00","total_whole":"1,474,902","shares_owned_after":470000.0,"shares_owned_after_display":"470,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-13","filed_date":"2023-06-13","scope":"insider"},{"id":8154322,"accession":"0001209191-23-036624","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-036624","line_url":"/filing/0001209191-23-036624#line-1","is_derivative":false,"issuer_cik":"0001507678","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001507678","owner_cik":"0001507678","owner_name":"Legorreta Pablo G.","owner_display_name":"Legorreta Pablo G.","owner_url":"/insider/0001507678","role":"Director, Officer (CEO, Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, Chairman of the Board","security_title":"Class A ordinary shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":45000.0,"shares_display":"45,000","price_per_share":32.9988,"price_display":"33.00","price_state":"stated","total_value":1484946.0,"total_display":"1,484,946.00","total_whole":"1,484,946","shares_owned_after":425000.0,"shares_owned_after_display":"425,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-12","filed_date":"2023-06-13","scope":"insider"},{"id":8216178,"accession":"0000950103-23-007785","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950103-23-007785","line_url":"/filing/0000950103-23-007785#line-1","is_derivative":false,"issuer_cik":"0001507678","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001507678","owner_cik":"0001507678","owner_name":"Legorreta Pablo G.","owner_display_name":"Legorreta Pablo G.","owner_url":"/insider/0001507678","role":"Director, Officer (CEO, Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, Chairman of the Board","security_title":"Class A ordinary shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":32.2496,"price_display":"32.25","price_state":"stated","total_value":4837440.0,"total_display":"4,837,440.00","total_whole":"4,837,440","shares_owned_after":380000.0,"shares_owned_after_display":"380,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-24","filed_date":"2023-05-24","scope":"insider"},{"id":7995021,"accession":"0000950103-23-007427","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950103-23-007427","line_url":"/filing/0000950103-23-007427#line-2","is_derivative":false,"issuer_cik":"0001507678","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001507678","owner_cik":"0001507678","owner_name":"Legorreta Pablo G.","owner_display_name":"Legorreta Pablo G.","owner_url":"/insider/0001507678","role":"Director, Officer (CEO, Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, Chairman of the Board","security_title":"Class A ordinary shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":69612.0,"shares_display":"69,612","price_per_share":32.9411,"price_display":"32.94","price_state":"stated","total_value":2293095.8532,"total_display":"2,293,095.85","total_whole":"2,293,096","shares_owned_after":230000.0,"shares_owned_after_display":"230,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-17","filed_date":"2023-05-17","scope":"insider"},{"id":7995017,"accession":"0000950103-23-007427","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950103-23-007427","line_url":"/filing/0000950103-23-007427#line-1","is_derivative":false,"issuer_cik":"0001507678","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001507678","owner_cik":"0001507678","owner_name":"Legorreta Pablo G.","owner_display_name":"Legorreta Pablo G.","owner_url":"/insider/0001507678","role":"Director, Officer (CEO, Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, Chairman of the Board","security_title":"Class A ordinary shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":160388.0,"shares_display":"160,388","price_per_share":33.5669,"price_display":"33.57","price_state":"stated","total_value":5383727.9572,"total_display":"5,383,727.96","total_whole":"5,383,728","shares_owned_after":160388.0,"shares_owned_after_display":"160,388","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-16","filed_date":"2023-05-17","scope":"insider"},{"id":6531969,"accession":"0000899243-22-003857","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-003857","line_url":"/filing/0000899243-22-003857#line-1","is_derivative":false,"issuer_cik":"0001507673","issuer_name":"Epizyme, Inc.","issuer_ticker":"EPZM","issuer_name_source":null,"issuer_url":"/issuer/0001507673","owner_cik":null,"owner_name":"RPI Finance Trust; Legorreta Pablo G.; RP Management, LLC","owner_display_name":"RPI Finance Trust","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":22666667.0,"shares_display":"22,666,667","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":34000000.5,"total_display":"34,000,000.50","total_whole":"34,000,001","shares_owned_after":31833334.0,"shares_owned_after_display":"31,833,334","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-02-01","scope":"insider"},{"id":2210329,"accession":"0000950103-20-012150","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950103-20-012150","line_url":"/filing/0000950103-20-012150","is_derivative":false,"issuer_cik":"0001507678","issuer_name":"Royalty Pharma plc","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0001507678","owner_cik":"0001507678","owner_name":"Legorreta Pablo G.","owner_display_name":"Legorreta Pablo G.","owner_url":"/insider/0001507678","role":"Director, Officer (CEO, Chairman of the Board), Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO, Chairman of the Board","security_title":"Class A Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":28.0,"price_display":"28.00","price_state":"stated","total_value":560000.0,"total_display":"560,000.00","total_whole":"560,000","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-18","filed_date":"2020-06-22","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":8,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":8,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":8},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001850270","name":"PROKIDNEY CORP.","url":"/issuer/0001850270","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2024-06-14","last_seen":"2024-06-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001802768","name":"Royalty Pharma plc","url":"/issuer/0001802768","role":"Director, Officer (CEO, Chairman of the Board), Ten percent owner","n_filings":5,"first_seen":"2020-06-22","last_seen":"2023-06-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001571498","name":"Epizyme, Inc.","url":"/issuer/0001571498","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2022-02-01","last_seen":"2022-02-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001507678","retrieved_at":"2026-08-25T14:59:33+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}